Tobira/Dong-A Partnership Will Add DPP-4 Inhibitor For NASH Combo Therapy
California biotech acquires rights to Suganon, approved for type 2 diabetes in South Korea, while partner Dong-A gets domestic rights to NASH candidate cenicriviroc.
California biotech acquires rights to Suganon, approved for type 2 diabetes in South Korea, while partner Dong-A gets domestic rights to NASH candidate cenicriviroc.